Previous studies have shown that axonal mitochondrial transport can be increased by targeting mitochondrial biogenesis, through PGC1α over expression, as a potential therapy for neurodegenerative disorders [50].This potential therapeutic strategy, however, has not been applied to demyelinating disorders. The gene discussed is PPARGC1A; the disease is demyelinating disease.